Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CIGB300 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CIGB300 | Drug | CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with presence or absence of grade 3 or 4 adverse events related to the study drug, in each dose level | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with local relapses | Up to 2 years | |
| Number of patients with distant relapses | Up to 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto de Oncologia Angel H. Roffo | Ciudad Autonoma de Buenos Aires | Buenos Aires | C1417DTB | Argentina |
Not provided
| ID | Term |
|---|---|
| C532510 | CIGB-300 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided